Alloplex will participate in the CHI’s 7th Annual Immuno-Oncology Summit Europe

Boston, MA, USA  — June 14, 2023. 

Alloplex Biotherapeutics’ Founder and CEO, Dr. Frank Borriello, is a speaker within the Gamma Delta Immunotherapy ‘Exploiting and Enhancing Unique Properties for Cancer Treatment’ track of the CHI Immuno-Oncology Summit Europe, taking place in London from June 20 to 22, 2023.

His presentation, entitled ‘SUPLEXA platform for reprogramming of immune cells for the treatment of cancer’, will take place on Tuesday 20th June at 12.10 p.m.. Dr. Borriello looks forward to seeing you and catching up on the latest Gamma Delta T cell developments.

More about SUPLEXA therapeutic cells

SUPLEXA therapeutic cells represent a novel approach to adoptive cellular therapy involving the activation, differentiation, and expansion of peripheral blood mononuclear cells to broadly target cancer while sparing normal tissues. 

  • An autologous cellular therapy comprised of multiple immune cell types including NK, NK-T, γδ T cells, and  αβ CTL
  • Ongoing Phase 1 clinical trial safety and efficacy update
  • Summary of exploratory longitudinal PBMC and plasma analyses from treated patients suggests a potential approach to pharmacodynamic monitoring of SUPLEXA cell activity
  • The absence of drug-related adverse events facilitates future single-agent dose optimization efforts and plans for combination studies.

Cambridge Healthtech Institute (‘CHI’) on Cellular Therapies

CHI stated “Cellular therapies are showing exciting potential for improved treatment of cancer, with gamma-delta T cells providing unique advantages for further development. Gamma-delta T cells represent up to 5% of a person’s T cell population, and higher levels of gamma-delta T cells within a tumor is strongly correlated with better prognosis and increased survival. Researchers are exploring a range of ways to take advantage of these properties and ways to enhance them for effective treatment. This includes broad antigen recognition, multivalent responses and the lack of MHC restrictions. These properties are being enhanced via different strategies for expansion, engineering and genetic modification to increase cytotoxicity or increased tumor-specific targeting. While much of the development in this field is still at preclinical stage an increasing number of products are entering the clinic with promising potential.”